Univest Securities Closes $5.1 Million Private Placement for Qualigen Therapeutics

Univest Securities, LLC has announced the successful closing of a $5.1 million private placement for Qualigen Therapeutics, Inc., a company focused on developing treatments for cancers. The placement involved 5,100 Series A-2 Preferred Shares, each valued at $1,000. The securities were offered under Section 4(a)(2) of the Securities Act of 1933 and Rule 506(b) of Regulation D. They are not registered under the Act, thus cannot be sold in the U.S. without SEC registration or an exemption. Qualigen has agreed to file a registration statement with the SEC for the resale of the common shares and warrants within fourteen days post-closing. Univest Securities acted as the sole placement agent for this transaction.